Patent DE815457C successfully refreshed from Google Patents.
Patent US4740587A successfully refreshed from Google Patents.
US4740587A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibin and method of purifying same
Assignee: Salk Institute for Biological Studies
•
Filing: 1985-10-03
•
Granted: 1988-04-26
•
Expires: 2005-10-03
Abstract
Abstract Two 32,000-dalton proteins with inhibin activity were isolated from porcine follicular fluid using heparin-Sepharose affinity chromatography, followed by gel filtration on Sephacryl S-200 and then four steps of reverse-phase high-performance liquid chromatography. Each isolated molecular is composed of two chains having molecular weights of about 18,000 and about 14,000 daltons, respectively, which are bound together by disulfide bonding. Microsequencing revealed the NH 2 -terminal portion of the 18K chain of both to be Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val, of one of the 14K chains to be Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp, and of the other 14K chain to be Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro. Both proteins have now been completely characterized, each having a first chain 134 residues long linked by disulfide bonding to a second chain 116 or 115 residues long. The first chain is believed to be glycosylated, which accounts for the disparity between the number of residues and the apparent molecular weight of 18K. These 32K proteins specifically inhibit basal secretion of FSH, but not of LH, in a rat anterior pituitary monolayer culture system. The half-maximal effective does of one is 450 pg/ml and of the other is 900 pg/ml.
Inventors
- 👤 Nicholas C. Ling
- 👤 Shao-Yao Ying
- 👤 Fred S. Esch
- 👤 Roger C. L. Guillemin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:17
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/26
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
110 words
A 32,000-dalton protein having a purity of at least about 90% by weight of total proteins, said protein having a pKa of about 4.8, said protein being composed of a first polypeptide chain having a molecular weight of about 18,000 and a second polypeptide chain having a molecular weight of about 14,000 daltons, said first chain and said second chain being linked to each other through disulfide bonding in the active protein, said first chain having an amino-terminal sequence beginning with Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val and said second chain having an amino-terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly, said protein specifically inhibiting basal secretion of follicle-stimulating hormone while not inhibiting basal secretion of luteinizing hormone.
Claim 2
Dependent Claim
110 words
A 32,000-dalton protein having a purity of at least about 90% by weight of total proteins, said protein having a pKa of about 4.8, said protein being composed of a first polypeptide chain having a molecular weight of about 18,000 and a second polypeptide chain having a molecular weight of about 14,000 daltons, said first chain and said second chain being linked to each other through disulfide bonding in the active protein, said first chain having an amino-terminal sequence beginning with Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val and said second chain having an amino-terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly, said protein specifically inhibiting basal secretion of follicle-stimulating hormone while not inhibiting basal secretion of luteinizing hormone.
Claim 3
Dependent Claim
18 words
A protein according to claim 1 wherein said second chain has an amino terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu.
Claim 4
Dependent Claim
26 words
A protein according to claim 1 wherein said second chain has an amino terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-X-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp, wherein X is an unknown amino acid residue.
Claim 5
Dependent Claim
15 words
A protein according to claim 1 wherein said second chain has the amino-terminal sequence: H-Gly-Leu-Glu-cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro.
Claim 6
Dependent Claim
15 words
A protein according to claim 1 wherein said second chain has the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val- le-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH.
Claim 7
Dependent Claim
50 words
A protein according to claim 1 having an amino acid composition of about Asx 21.0, Thr 13.5. Ser 18.1, Glx 22.5, Gly 22.4, Ala 22.0, Val 14.4, Met 5.8, Ile 10.3, Leu 27.8, Tyr 11.4, Phe 10.0, His 7.9, Trp 3.9, Lys 5.4, Arg 15.8, Cys 14.2, and Pro 29.6.
Claim 8
Dependent Claim
50 words
A protein according to claim 1 having an amino acid composition of about Asx 18.5, Thr 11.5. Ser 16.3, Glx 21.3, Gly 19.9, Ala 19.7, Val 14.1, Met 6.1, Ile 14.6, Leu 27.3, Tyr 10.7, Phe 11.6, His 14.1, Trp 4.4, Lys 11.9, Arg 13.9, Cys 14.4, and Pro 29.2.
Claim 9
Dependent Claim
19 words
A protein according to claim 1 wherein said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly- ys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn- eu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH and is glycosylated.
Claim 10
Dependent Claim
16 words
A protein according to claim 5 wherein said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly- ys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn- eu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH.
Claim 11
Dependent Claim
15 words
A protein according to claim 1 wherein said second chain has the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val- al-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH
Claim 12
Dependent Claim
16 words
A protein according to claim 10 wherein said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly- ys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn- eu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH.
Claim 13
Independent Claim
67 words
A method of obtaining substantially homogeneous proteins having inhibin activity from crude extracts comprising procuring extract material having inhibin activity, exposing said extract to a support medium to which heparin moieties are attached under such conditions that inhibin proteins adsorb to said heparin moieties, and subsequently eluting said inhibin proteins from said heparin moieties, gel filtrating said eluted inhibin proteins and selecting fractions having inhibin activity, and
Claim 14
Independent Claim
67 words
A method of obtaining substantially homogeneous proteins having inhibin activity from crude extracts comprising procuring extract material having inhibin activity, exposing said extract to a support medium to which heparin moieties are attached under such conditions that inhibin proteins adsorb to said heparin moieties, and subsequently eluting said inhibin proteins from said heparin moieties, gel filtrating said eluted inhibin proteins and selecting fractions having inhibin activity, and
Claim 15
Dependent Claim
15 words
fractionating said gel filtrated fractions on at least one reverse-phase high performance liquid chromatography column.
Claim 16
Dependent Claim
15 words
fractionating said gel filtrated fractions on at least one reverse-phase high performance liquid chromatography column.
Claim 17
Dependent Claim
31 words
A method according to claim 12 wherein said gel filtrated fractions are fractionated on at least two successive reverse-phase high performance liquid chromatography columns of different solid and/or liquid phase conditions.
Claim 18
Dependent Claim
31 words
A method according to claim 12 wherein said gel filtrated fractions are fractionated on at least four successive reverse-phase high performance liquid chromatography columns of different solid and/or liquid phase conditions.
Claim 19
Dependent Claim
15 words
A method according to claim 12 wherein said RP-HPLC is performed on a C3-C5 column.
Claim 20
Dependent Claim
18 words
A method according to claim 12 wherein the liquid phase in said RP-HPLC is a gradient of acetonitrile.
Claim 21
Dependent Claim
16 words
A method according to claim 12 wherein said crude extract is obtained from porcine body material.
Claim 22
Dependent Claim
14 words
A method according to claim 17 wherein said body material is porcine follicular fluid.
Claim 23
Dependent Claim
41 words
A synthetic protein produced by recombinant DNA techniques or the like having two chains interconnected by disulfide bonding, said first chain having formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp- Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pr -Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH and said second chain having either the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val- le-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH, or the formula H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val- al-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH.
Claim 24
Dependent Claim
41 words
A synthetic protein produced by recombinant DNA techniques or the like having two chains interconnected by disulfide bonding, said first chain having formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp- Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pr -Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH and said second chain having either the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val- le-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH, or the formula H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val- al-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH.
Claim 25
Dependent Claim
31 words
A synthetic protein useful for the production of synthetic inhibin, which protein is selected from the group consisting of: (a) H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly- ys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn- eu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH; (b) H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val- al-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr- sn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH and (c) H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-I e-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH.
Claim 26
Dependent Claim
31 words
A synthetic protein useful for the production of synthetic inhibin, which protein is selected from the group consisting of: (a) H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly- ys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn- eu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH; (b) H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val- al-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr- sn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH and (c) H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-I e-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-26 | 1991-10-26 | 1992-04-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-26 | 1995-10-26 | 1996-04-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-26 | 1999-10-26 | 2000-04-26 | $7700.00 | Window Closed / Lapsed |